Abstract： Objective： To observe the clinical effect of Tiaoqi Dingxian Prescription combined with western medicine on epilepsy of qi constraint and phlegm stagnation type. Methods：A total of 60 cases of patients of epilepsy of qi constraint and phlegm stagnation type admitted to Maoming Hospital Affiliated to Guangzhou University of Chinese Medicine from June 2023 to July 2024 were selected as the research subjects. They were randomly divided into the control group and the observation group using a random number table method，with 30 cases in each group. The control group was treated with Levetiracetam，while the observation group was treated with Tiaoqi Dingxian Prescription on the basis of the control group. Both groups were treated for three months，and the clinical effficacy，frequency and duration of onset of epilepsy improvement of electroencephalogram （EEG），Quality of Life in Epilepsy Inventory （QOLIE-31） scores， traditional Chinese medicine（TCM） syndrome scores， and incidence of adverse reactions were evaluated in both groups. Results：The total effective rate was 93.33%（ 28/30） in the observation group，while that of 73.33%（ 22/ 30） in the control group， the difference being significant （P＜0.05）. After treatment， the frequency and duration of onset of epilepsy in both groups were decreased when compared with those before treatment （P＜0.05）， and the frequency and duration of onset of epilepsy in the observation group were lower than those in the control group （P＜ 0.05）. After treatment，the EEG grading of both groups was improved when compared with that before treatment （P＜ 0.05）， and the EEG grading in the observation group was better than that in the control group （P＜0.05）. After treatment，the QOLIE-31 scores in both groups，including anxiety，overall health level，emotional health，energy， cognitive function， medication effects， and social function， were increased when compared with those before treatment （P＜0.05），and all scores in the observation group were higher than those in the control group （P＜0.05）. After treatment， the TCM syndrome scores in both groups were decreased when compared with those before treatment （P＜0.05）， and the scores in the observation group were lower than those in the control group （P＜0.05）. The incidence of adverse reactions was 6.67% （2/30） in the observation group，13.33% （4/30） in the control group， and there was no significant difference between the two groups （P＞0.05）. Conclusion： The combination of Tiaoqi Dingxian Prescription and Levetiracetam in the treatment of epilepsy of qi constraint and phlegm stagnation type can improve clinical efficacy，alleviate patient's symptoms and quality of life，and has good safety.